Seeking Alpha’s Jason Chew writes about Biovista’s Drug Repositioning approach:

Following up my previous piece on drug repositioning by Orexigen with its diet pill, Contrave, I spoke with Dr. Aris Persidis, President and co-founder of Biovista- a leading company in the drug repositioning business. Drug repositioning is the discovery and development of novel indications for approved drugs.

As Dr. Persidis told me in a phone interview, while studying drug treatment adverse effects (AEs), he and brother Andreas realized AEs themselves- as a result of a drug’s mechanism of action- represented therapeutic opportunities for that drug. Seeing a need in the pharmaceutical industry for such discovery services they launched Biovista together in 1996.

Read More: